KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) FCF Margin (2016 - 2025)

West Pharmaceutical Services' FCF Margin history spans 17 years, with the latest figure at 21.74% for Q4 2025.

  • For Q4 2025, FCF Margin fell 3291.0% year-over-year to 21.74%; the TTM value through Dec 2025 reached 15.25%, down 550.0%, while the annual FY2025 figure was 15.25%, 550.0% down from the prior year.
  • FCF Margin for Q4 2025 was 21.74% at West Pharmaceutical Services, up from 16.64% in the prior quarter.
  • Across five years, FCF Margin topped out at 59.99% in Q4 2023 and bottomed at 6.75% in Q3 2024.
  • The 5-year median for FCF Margin is 13.58% (2025), against an average of 19.17%.
  • The largest annual shift saw FCF Margin surged 4311bps in 2022 before it tumbled -3291bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 11.54% in 2021, then surged by 374bps to 54.65% in 2022, then grew by 10bps to 59.99% in 2023, then dropped by -9bps to 54.65% in 2024, then crashed by -60bps to 21.74% in 2025.
  • Per Business Quant, the three most recent readings for WST's FCF Margin are 21.74% (Q4 2025), 16.64% (Q3 2025), and 13.29% (Q2 2025).